Related Videos
More from this user
Related Groups
More on Sciencestage.com
ecancertv  |
(0) (0 Votes)
|
Views: (295) Date: (07-04-10) Time: (00:03:12) |
Description: Dr. Vincent A. Miller - MD Memorial Sloan-Kettering Cancer Center, New York, USA ASCO press conference: A phase III trial finds that adding erlotinib (Tarceva) to bevacizumab-based (Avastin) maintenance therapy in patients with advanced NSCLC delays cancer progression more than maintenance treatment with bevacizumab alone.
Related Documents
Related Wikipedia Results
Related Pubmed Results
Related Nature.com Results
Related Answers.com Results